PLIANT THERAPEUTICS, INC. (PLRX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US7291391057
PLIANT THERAPEUTICS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -156.37 m USD |
| EBIT | -146.79 m USD |
| Net income | -149.34 m USD |
| Diluted EPS – continuing operations | -2.43 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PLIANT THERAPEUTICS, INC.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
More stocks
- d1000 Varejo Farma Participações S.A (DMVF3.SA)
- HARVARD BIOSCIENCE INC (HBIO)
- Energous Corp (WATT)
- Samil C&S Co Ltd (004440.KS)
- CMG Pharmaceutical Co. Ltd (058820.KQ)
- BATTALION OIL CORP (BATL)
- Abcourt Mines Inc. (ABI.V)
- Connect Biopharma Holdings Ltd (CNTB)
- Histeel (071090.KS)
- TSI Co. Ltd. (277880.KQ)
- Wiable Corp (065530.KQ)
- Pan Global Resources Inc (PGZ.V)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.